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Summary
Objective: To evaluate the measurement properties of a new osteoarthritis (OA) pain measure.
Methods: The new tool, comprised of 12 questions on constant vs intermittent pain was administered by phone to 100 subjects aged 40þ
years with hip or knee OA, followed by three global hip/knee questions, the Western Ontario and McMaster Universities (WOMAC) pain
subscale, the symptom subscales of the Hip Disability and OA Outcome Score (HOOS) or Knee Injury and OA Outcome Score (KOOS),
and the limitation dimension of the Late Life Function and Disability Instrument (LLFDI). Testeretest reliability was assessed by re-
administration after 48e96 h. Item response distributions, inter-item correlations, item-total correlations and Cronbach’s alpha were assessed.
Principle component analysis was performed and testeretest reliability was assessed by intra-class correlation coefﬁcient (ICC).
Results: There was good distribution of response options across all items. The mean intensity was higher for intermittent vs constant pain,
indicating subjects could distinguish the two concepts. Inter-item correlations ranged from 0.37 to 0.76 indicating no item redundancy. One
item, predictability of pain, was removed from subsequent analyses as correlations with other items and item-total correlations were low.
The 11-item scale had a corrected inter-item correlation range of 0.54e0.81 with Cronbach’s alpha of 0.93 for the combined sample. Principle
components analysis demonstrated factorial complexity. As such, scoring was based on the summing of individual items. Testeretest reliabil-
ity was excellent (ICC 0.85). The measure was signiﬁcantly correlated with each of the other measures [Spearman correlations 0.60 (KOOS
symptoms) to 0.81 (WOMAC pain scale)], except the LLFDI, where correlations were low.
Conclusions: Preliminary psychometric testing suggests this OA pain measure is reliable and valid.
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410 G. A. Hawker et al.: Psychometric testing of a new OA pain measureIntroduction chronic pain disorder, such as diabetic neuropathy, were excluded. In addi-
tion, hip participants experiencing radicular pain were not eligible.In prior research, we conducted focus groups to examine
the pain experience of people with hip/knee osteoarthritis
(OA) from early to late disease, including those aspects of
the pain experience that were considered most distressing.
These focus group discussions identiﬁed two distinct types
of pain in OA e an aching and fairly constant background
pain and a less frequent, but more intense and often unpre-
dictable pain1. Of these, intermittent but intense pain, par-
ticularly when not predictable, had a greater impact on
quality of life than did background aching pain. These
data suggest that the evaluation of pain in people with hip
or knee OA needs to include questions that ask about
both constant and intermittent pain taking into account
both pain intensity and impact on quality of life. To our
knowledge, no such measure exists. Hence, using the
data from these focus groups to generate items, we devel-
oped a new pain measure for hip/knee OA, the Measure of
Intermittent and Constant Osteoarthritis Pain (ICOAP), suit-
able for use by clinicians to document progression or wors-
ening of pain, response to therapy and indication for need
for referral to surgery for consideration of joint replacement.
Here we report the preliminary psychometric testing of this
measure.MethodsITEM GENERATIONItem generation was performed using standardized focus groups
described in detail elsewhere1. Brieﬂy, we used a ‘‘funnel approach’’,
starting with broad open-ended questions about the characteristics of
the hip/knee pain over time, and then increasingly focused on more spe-
ciﬁc issues, including those aspects of the pain that participants found
most distressing. Following these discussions, a modiﬁcation of Ruta
et al.’s2. Patient Generated Index (PGI) was used to further assess the
priorities and concerns of individuals living with hip or knee OA pain.
Focus group transcripts were reviewed independently by two or more re-
searchers to identify distinct themes. Content analysis was then performed
on the coded transcripts to examine for trends in responses over time from
early to late disease. PGI responses were analyzed descriptively. Summa-
ries of our ﬁndings were created for hips and knees, separately, and
disseminated to participants, investigators and focus group moderators
to ensure they reﬂected what they heard in their particular group.THE NEW PAIN MEASUREThe 12-item measure, developed based on focus group results, was com-
prised of two sections, one for ‘constant pain’ and one for ‘pain that comes
and goes’. For each of these pain types, single items assessed pain inten-
sity, affect on sleep, impact on quality of life, extent to which the pain ‘frus-
trates or annoys’, and the extent to which it ‘worries or upsets’. For pain
that comes and goes, two additional items asked respondents to report the
frequency of pain and the degree to which the pain could be predicted.
The time frame used was 1 week, in keeping with other widely used OA
pain measures. All items were constructed as rating scales, with ﬁve levels
of response (0e4) e for questions asking about intensity, response options
were ‘not at all’ (0), ‘mildly’, ‘moderately’, ‘severely’ and ‘extremely’ (4), while
those that asked about frequency had the following response options: ‘never’
(0), ‘rarely’, ‘sometimes’, ‘often’, and ‘very often’ (4). People with OA re-
viewed the questionnaire for wording and to ensure correct interpretation
of the items prior to testing of the measurement properties.
Preliminary testing of the measurement properties was performed in 100
individuals with hip (n¼ 18) or knee OA (n¼ 82) living in Ontario, Canada
drawn from investigators’ clinical practices, joint replacement wait lists, and
from among the members of an existing OA cohort. Those eligible to partic-
ipate were: English-speaking men and women with hip or knee OA, aged
40þ years, who responded ‘‘yes’’ to the question: ‘‘Have you experienced
aching, discomfort, pain and/or stiffness in or around a hip or knee on
most days of at least 1 month (15 or more days of the month) during the
past year?’’. In addition, participants had not experienced an injury to
the joint area within the last year, or had a total joint replacement (TJR) of
the symptomatic joint. Subjects with rheumatoid arthritis or any other type
of inﬂammatory arthritis, ﬁbromyalgia, chronic low back pain, or anotherQUESTIONNAIRE ADMINISTRATIONQuestionnaires were administered over the phone. The two components
of the tool, constant pain and pain that comes and goes, were administered
in random order, followed by three global hip/knee questions (In the past
week, how frustrated or annoyed have you been by your hip/knee prob-
lems?; In the past week, how upset or worried have you been by your hip/
knee problems?; In the past week, how much has your overall quality of
life been affected by your hip/knee problems?), and ﬁnally ﬁve questions
to obtain feedback from the participants regarding unclear, difﬁcult or uncom-
fortable questions, inappropriate response categories and acceptability of in-
terview length. A ﬁnal section was comprised of questions taken from
existing validated OA measures, in order to assess the validity of the new
tool. These included the pain subscale of the Western Ontario and McMaster
Universities (WOMAC) OA Index3, the symptoms subscale of the Hip Dis-
ability and OA Outcome Score (HOOS)4 or Knee Injury and OA Outcome
Score (KOOS)5 and the limitation dimension of the Late Life Function and
Disability Instrument (LLFDI)6,7. Demographics such as age, sex, education
and whether they were on a wait list for or had ever had a TJR were also
collected.
Testeretest reliability was assessed by re-administration to subjects who
agreed to be contacted again. The same interviewer contacted them again
between 48 and 96 h after the ﬁrst interview and repeated the new instru-
ment only. The questionnaire was not completed if the participant reported
that they had experienced any change in their pain since completion of the
ﬁrst interview. If the original interviewer was unable to contact the subject
at the prearranged time, another interviewer completed the re-contact
(n¼ 16).STATISTICAL ANALYSISItem-level analyses
The distribution of item responses was evaluated, including the response
option frequencies and mean, standard deviation (SD) and median scores
for each item. Item responses were compared for individuals with hip vs
knee OA, and by gender, using chi square analysis. Where differences
were observed for the hip vs knee, we also assessed for differences by gen-
der within each joint group. Inter-item correlations were determined using
Spearman or Kendall’s tau, depending on the distribution of responses
and potential need to collapse item response categories based on response
frequencies. Corrected item-total correlations were also calculated. Correla-
tions in the approximate range of 0.30e0.70 are desirable as lower values
would indicate lack of homogeneity and high correlations would indicate
item redundancy8.
As most inter-item correlations were in the desired range, Cronbach’s al-
pha was calculated for all items and the constant and intermittent pain items
to determine scale homogeneity where Cronbach’s alpha of 0.80 was
considered a minimum standard for creating a summated score9,10. Principle
component analysis with varimax rotation and then with promax rotation was
performed to determine whether the constant and intermittent pain func-
tioned as separate domains or whether the questionnaire score was best re-
ﬂected as a single dimension.
Testeretest reliability
Among those who reported no change in pain, the intra-class correlation
coefﬁcient (ICC) (version 2) was calculated as a measure of testeretest
reliability11. For the initial stages of test development, an ICC of at least
0.80 is required to minimize measurement error while 0.90 or greater is
preferred12,13.
Validity testing
Content and face validity were determined a priori through development of
the instrument based on data derived through patient focus groups, outlined
above. Thus, the initial focus here was on preliminary assessment of con-
struct validity. We hypothesized the following: the new measure would corre-
late modestly with the WOMAC pain and the HOOS/KOOS symptom
subscales (intra-class correlation of 0.40e0.70); intermittent pain would
have a higher correlation with the LLFDI score than constant pain; females
would tend to report higher levels of pain than males, consistent with prior
research in OA; and, the impact of pain on quality of life would be greater
in those with greater pain and greater unpredictability of pain on the new
measure.
There was no differential item functioning by hip or knee and the results
for reliability and validity testing, although in a small sample of people with
411Osteoarthritis and Cartilage Vol. 16, No. 4hip OA, were similar. As such, all analyses were conducted for the hip sam-
ple alone, the knee sample alone and then the combined group.
Ethics approval was obtained from the Sunnybrook and Women’s College
Health Sciences Centre Research Ethics Board.Results
The new measure was pilot tested in 18 individuals with
hip OA and 82 with knee OA; of these, 12 and 64, respec-
tively, participated in the retest. Characteristics of the partic-
ipants by index joint (hip or knee) are presented in Table I.
The mean age of participants with hip and knee OA was
similar, at 72.1 9.0 years and 75.4 9.6 years, respec-
tively (range overall 51e93 years); 78.0% of participants
were female. Approximately 68% of participants had
a high school education or less, and four (22.2%) hip and
three (3.7%) knee participants were on a wait list for joint re-
placement surgery. The mean WOMAC pain subscale
scores were similar for hip and knee participants, at 7.8/
20 (3e16) and 8.2/20 (0e19), respectively. Hip participants’
HOOS symptom scores and knee participants’ KOOS
symptom scores were similarly distributed across the range
of possible values. LLFDI e limitation scores were
70.0 15.9, 60.3 9.0 and 62.1 11.2 for hips, knees
and all subjects, respectively.
Descriptive analyses of the items demonstrated good dis-
tribution of response options (i.e., use of the entire scale)
across all items (see Table II for distributions for combined
hip and knee sample). Of note, given that the mean inten-
sity for intermittent as compared to constant pain was
higher (2.0/4 vs 1.6/4, P¼ 0.003), it appeared that subjects
could distinguish the two types of pain and that intermittent
pain was of greater intensity as had been indicated in the
focus groups and interviews1. One hip participant and two
knee participants reported having only constant pain.
The inter-item correlations ranged from 0 to 0.90, 0.29 to
0.81, and 0.30 to 0.75 for each of the hip, knee and com-
bined samples, respectively, indicating no item redundancy.
In each case the lowest inter-item correlations were with the
same item (predictability of pain that comes and goes),
which correlated with each of the other items in the range
of 0.03e0.47. This item was problematic in both the hip
and knee samples, where the corrected item-total correla-
tions were low (<0.30); Cronbach’s alpha increased with
the removal of this item. Removing this item in all subse-
quent analyses, Cronbach’s alpha was 0.95, 0.93 and
0.93 for the hip, knee and combined samples, respectively.
Cronbach’s alpha was above 0.85 for constant pain andTable
Demographic character
Characteristic Hip sample (n¼
Age e mean (minemax) 72.1 (52e8
Female e n (%) 14 (78%)
Level of education e n (%)
<High school 4 (22%)
Completed high school 7 (39%)
Post-secondary 7 (39%)
On a joint replacement wait list e n (%) 4 (22%)
WOMAC pain subscale (/20), meanSD (range) 7.8 3.3 (3e16
HOOS symptom subscale, meanSD (range) 62.8 22.5 (10e9
KOOS symptom subscale, meanSD (range) e
LLFDI
Limitation dimension 70.0 15.9 (41.5e
Instrumental role 69.6 19.3 (33.7e
Management role 84.6 14.2 (60.1eintermittent pain for each of the hip, knee and combined
samples.
Given the high Cronbach’s alpha, we used principle com-
ponent analysis with varimax rotation to evaluate whether
constant and intermittent pain would be best represented
by two domains of pain rather than a single construct. This
analysis was done only for the total sample as we had insuf-
ﬁcient power to perform analyses by hip and knee, sepa-
rately. In an exploratory analysis using eigenvalue¼ 1
criteria to consider retaining factors, three factors were
extracted that explained 81.7% of the variance (factor 1¼
54.9%, factor 2¼ 16.8%, factor 3¼ 10.0%). The solution
was complex with multiple loadings of >0.40 across factors.
Eight (ﬁve constant pain and three intermittent pain) of the
11 items loaded on the ﬁrst factor (loadings from 0.44 to
0.87) but four of these also loaded on the second factor as
well. Two items, constant pain affecting sleep and pain
that comes and goes affecting sleep, loaded on a third factor
but also demonstrated complexity in that they also loaded on
the ﬁrst factor. These two items may reﬂect sleep difﬁculty in
general as well as pain. Given the complexity of the results
from the orthogonal rotation, a solution was also obtained
using promax rotation. This solution further conﬁrmed the
complexity as all items with the exception of frequency of
pain that comes and goes, loaded on multiple factors. In
a further attempt to determine if there was reason to scale
the constant and intermittent pain separately, we looked at
whether either of these two types of pain was more highly
correlated with participants’ global ratings of (1) frustration,
(2) upset/worry or (3) quality of life. However, the correla-
tions were similar for constant and intermittent pain: 0.59
and 0.51, 0.21 and 0.13, and 0.24 and 0.35 (P< 0.01 for
all) for each of the global constructs, respectively. Based
on these results, our subsequent analyses were based on
a total summed score for the 11 items. In 76 individuals
who completed the pain measure twice, testeretest reliabil-
ity was excellent [ICC2¼ 0.85, 95% conﬁdence interval (CI):
0.76e0.91 for the combined sample].
The 11-item measure was signiﬁcantly correlated, and in
the directions expected, with the WOMAC pain scale, the
KOOS symptoms scale, and self-rated affect of hip/knee
problems on quality of life with Spearman correlation coefﬁ-
cients ranging in magnitude from 0.60 (KOOS symptoms) to
0.81 (WOMAC pain scale) (Table III). As predicted, scores
were slightly higher in women than men [mean score
17.4 (95% CI: 15.2e19.6) vs 15.0 (95% CI: 10.9e19.1)]
although not signiﬁcantly different. Our hypothesis that
intermittent pain would be more highly correlated withI
istics participants
18) Knee sample (n¼ 82) Combined sample (n¼ 100)
7) 75.4 (51e93) 74.8 (51e93)
64 (78%) 78 (78%)
34 (38%) 35 (38%)
23 (28%) 30 (30%)
28 (34%) 35 (35%)
3 (4%) 7 (7%)
) 8.2 4.4 (0e19) 8.1 4.2 (0e19)
0) e e
57.8 20.0 (0e93) e
100) 60.3 9.0 (39.6e83.4) 62.1 11.2 (39.6e100)
100) 57.2 11.3 (27.0e82.7) 59.5 13.9 (27.0e100)
100) 82.0 11.6 (51.7e100) 82.4 12.0 (51.7e100)
Table II
Item response option distributions
Item 0¼ not at all
(%)
1¼mildly
(%)
2¼moderately
(%)
3¼ severely
(%)
4¼ extremely
(%)
Mean
(median), SD
1. How intense has constant hip/knee pain been? 18 (18) 29 (29) 32 (32) 15 (15) 6 (6) 1.6 (2.0), 1.1
2. How much has your constant hip/knee pain
affected your sleep?
42 (42) 23 (23) 21 (21) 11 (11) 3 (3) 1.1 (1.0), 1.2
3. How much has your constant hip/knee pain
affected your overall quality of life?
27 (27) 24 (24) 27 (27) 17 (17) 5 (5) 1.5 (1.0), 1.2
4. How frustrated or annoyed have you been
by your hip/knee constant pain?
25 (25) 29 (29) 25 (25) 14 (14) 7 (7) 1.5 (1.0), 1.2
5. How upset or worried have you been by
your hip/knee constant pain?
44 (44) 20 (20) 23 (23) 8 (8) 5 (5) 1.1 (1.0), 1.2
6. How intense has your most severe hip/knee
pain that comes and goes been?
8 (8) 25 (25) 35 (35) 26 (26) 6 (6) 2.0 (2.0), 1.0
7. How frequently has this hip/knee pain
that comes and goes occurred?
6 (6) 14 (14) 25 (25) 34 (34) 21 (21) 2.5 (3.0) 1.2
8. How much has your hip/knee pain
that comes and goes affected your sleep?
42 (42) 20 (20) 22 (22) 13 (13) 2 (2) 1.1 (1.0), 1.2
9. How much has your hip/knee pain that come
and goes affected your overall quality of life?
17 (17) 35 (35) 32 (32) 10 (10) 6 (6) 1.5 (1.0), 1.1
10. How frustrated or annoyed have you been
by your hip/knee pain that comes and goes?
25 (25) 31 (31) 25 (25) 14 (14) 5 (5) 1.4 (1.0), 1.2
11. How upset or worried have you been by
your hip/knee pain that comes and goes?
44 (44) 24 (24) 21 (21) 8 (8) 3 (3) 1.0 (1.0), 1.1
412 G. A. Hawker et al.: Psychometric testing of a new OA pain measureLLFDI e limitations subscale was not supported as the
correlations were of very small magnitude (i.e., <0.3) and
not statistically signiﬁcantly different than zero for the hip,
knee or combined samples.Discussion
This study evaluated the preliminary psychometric prop-
erties of a new OA pain measure, ICOAP. The measure,
developed based on focus groups conducted in people liv-
ing with painful hip and knee OA residing in four English-
speaking countries, includes evaluation of two distinct types
of pain e constant pain and pain that comes and goes e
that were identiﬁed by people with OA as important. Prelim-
inary psychometric testing suggests the measure is reliable
and valid.
Content validity of the measure was achieved by our
methods of determining items. The relevance of items that
ask about the two types of pain is further supported by
our ﬁndings that the mean intensity for intermittent as com-
pared to constant pain was higher among study partici-
pants. This lends credence to the fact that people with OA
can indeed distinguish these two types of pain, and that
the OA pain experience is characterized by less severe,
aching constant pain punctuated by more intense but inter-
mittent pain, as was indicated in the focus groups1. AmongTable III
Spearman correlations between the new pain measure and other
measures
Comparator measure Combined sample (n¼ 100)
WOMAC pain subscale 0.811 (P< 0.001)
HOOS symptoms* 0.165 (P¼ 0.527)
KOOS symptomsy 0.600 (P< 0.001)
Self-reported quality of life 0.625 (P< 0.001)
LLFDI 0.154 (P¼ 0.145)
*Hip subjects only (n¼ 18).
yKnee subjects only (n¼ 82).our subjects, most of whom had moderate to severe hip or
knee OA, only three participants reported having only con-
stant pain and 12 reported having only intermittent pain,
consistent with our hypothesis that constant pain comes
later in the course of the arthritis pain experience.
Although our focus group ﬁndings suggested that the time
course for evolution of pain in hip OA is over an abbreviated
time period compared with knee OA, aspects of the pain that
were deemed distressing were similar for hip and knee OA
focus group participants. Nonetheless, we evaluated the
new tool separately for subjects with hip and knee OA to
evaluate for differential item functioning, and found none.
These preliminary ﬁndings suggest the tool can be used
similarly for patients with hip or knee OA; however, as our
sample size of hip pilot test participants was relatively small,
we recommend additional evaluation.
From focus group discussions23, it was clear that intermit-
tent but intense pain, particularly when not predictable, had
the most signiﬁcant impact on one’s quality of life, often
leading to signiﬁcant curtailing of activities. For this reason,
we initially included in the measure an item that asked
about the degree to which the pain that comes and goes
was predictable. Unfortunately, this item was found to
perform poorly; removal of this item improved the psycho-
metric properties of the measure. From pilot test partici-
pants’ feedback, we believe the main reason for this
item’s poor performance was the phrasing of this item,
which lead to variation in subjects’ interpretation of the
word ‘‘predictable’’. Although we have removed this item
from the measure at the present time, we encourage clini-
cians assessing pain in individuals with OA to ask about
the predictability of the pain, as well as the strategies they
employ, if any, to deal with this unpredictability when pres-
ent. As we continue the testing of the measure we will test
alternative wording for this predictability of intermittent pain
concept that people with OA have told us is an extremely
bothersome feature of their symptoms.
In conceptualizing this pain measure based on the focus
group data, we anticipated that we had an overall construct
of pain that was characterized by constant and intermittent
pain but it was unclear to us whether these characteristics
413Osteoarthritis and Cartilage Vol. 16, No. 4of the pain would result in a multi-dimensional measure or
a single construct. The Cronbach’s alpha values for the
constant and intermittent pain as well as for the combined
11 items were all high suggesting sufﬁcient homogeneity
to create a single summative scale. The complexity of the
factor analysis solutions was such that it was not clear that
subscale scores, rather than a single score should be
created. As such, we recommend that a total summative
score based on the 11 items be created and that this be
transformed to a 0e100 score where 0 represents no pain.
However, depending on the speciﬁc questions being asked,
investigators or clinicians may wish to also evaluate the
constant and intermittent pain separately based on scoring
as for the total pain measure. Additionally, two items, those
referring to the impact of constant and intermitting pain af-
fecting sleep, loaded on a third factor as well as on the ﬁrst
factor. This ﬁnding may indicate that responses to these two
items reﬂect underlying sleep disorders in addition to the di-
rect impact of pain on sleep (e.g., awakening due to pain).
Sleep disturbances are well recognized as common among
older people with OA13e15. In a large survey of older individ-
uals, complaints of insomnia or un-refreshing sleep were
twice as frequent among people with arthritis compared to
controls and that pain contributed signiﬁcantly to these sleep
complaints16. Prior work by our group has also documented
positive correlations between arthritis pain, fatigue and
sleepiness17. For these reasons, as further testing of the
measure is conducted we encourage ongoing testing of
the dimensionality of the measure.
In general, the new measure was signiﬁcantly correlated,
and in the directions expected, with the WOMAC pain and
the KOOS symptom subscales. As was expected, the cor-
relation between the WOMAC pain scale score and the
new pain measure was moderate, with a Spearman correla-
tion coefﬁcient of 0.81, indicating that the two measures are
evaluating different constructs. This level of correlation is
not surprising in light of the fact that the 5-item WOMAC
pain scale largely evaluates pain associated with speciﬁc
activities (correlations between the WOMAC pain and
physical function subscales have been consistently shown
to be very high, on the order of 0.8e0.918,19) while our
new measure evaluates aspects of the pain experience
alone, independent of function. A modest correlation be-
tween the new pain measure and the KOOS symptom sub-
scale was observed. This lower correlation is most likely
attributable to the differences in constructs between the
two scales. Our new pain measure assesses pain intensity,
related distress and impact of pain on quality of life while the
KOOS symptoms subscale captures physical symptoms
other than pain associated with the painful joint.
Surprisingly, the correlation between the LLFDI and the
new measure was low. There are several potential expla-
nations for this ﬁnding. First, our pilot test sample was gen-
erally comprised of older individuals, who may have given
up activities as a result of their age, as reﬂected by low
LLFDI scores, rather than because of their painful OA.
Second, we know from the literature that impairments
(like pain measures) correlate with activity in the range of
0.40e0.6020,21. However, relatively little is known about
how activity limitations and participation are related, but
based on research in other clinical areas, it seems likely
that they are probably similarly related, with correlations
of about 0.40 as well22. If impairments, activities and par-
ticipation are linear in relationship, the partial correlation
of pain to participation would be 0.25 if pain to activity is
0.5 and activity to participation is 0.5. Greater understand-
ing of the relationships between pain, activity andparticipation is needed before we can determine if our hy-
pothesis was incorrect.
Although preliminary testing supports the reliability and
validity of our new measure, there are some limitations
that must be considered, in addition to those already ad-
dressed. First, the measure was developed based on the
experiences of English-speaking people living with painful
OA. Since the development and validation of the pain tool
reported here were completed, the ICOAP has undergone
cross-cultural translation into multiple languages and further
validation in other hip and knee OA samples. The outcome
of this additional testing was very positive and reinforced
our conﬁdence in the ability of this new measure to capture
the aspects of pain that are most relevant to individuals with
OA. Based on this further work, minor modiﬁcations were
made to improve the succinctness of questionnaire section
framing. Second, pilot testing was performed mainly in indi-
viduals with moderately severe hip or knee OA. Evaluation
of the measurement properties of the new tool in individuals
with early OA is therefore needed. Finally, this ﬁrst study did
not assess the ability of the new tool to evaluate meaningful
changes in pain due to hip or knee OA over time or in re-
sponse to treatment. While additional studies are needed
to evaluate the ability of the ICOAP to measure changes
over time and to determine clinical cutpoints, we believe
that this tool is generalizable, suitable for use in research
and clinical settings, and addresses aspects of truth, dis-
crimination and feasibility as deﬁned by the OMERACT
ﬁlter23.
In summary, the new 11-item ICOAP comprehensively
evaluates the experience of pain among people living
with hip and knee OA. Consistent with what we learned
from extensive focus groups conducted in people with
painful hip/knee OA, the new measure evaluates, both
constant and intermittent pain and takes into account not
only pain intensity but also related distress and the impact
of OA pain on quality of life. Preliminary psychometric test-
ing suggests the measure is reliable and valid. Further
studies are required to conﬁrm these preliminary ﬁndings,
and to evaluate the responsiveness of this measure over
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